MedTrace Logo

Effect of Puerarin on Heart Health in Men

NCT03676296 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2021-04-29

No results posted yet for this study

Summary

This study aims to assess the effect of puerarin supplementation on cardiovascular disease risk factors in men.

Conditions

  • Cardiovascular Disease Risk Factors

Interventions

DRUG

Puerarin

Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks

DRUG

Placebo

Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks

Sponsors & Collaborators

  • Health and Medical Research Fund

    collaborator OTHER_GOV

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Gabriel M Leung, M.D. · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-05
Primary Completion
2021-04-17
Completion
2021-04-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03676296 on ClinicalTrials.gov